Sponsor Dossier

Haleon

Sponsor Dossier for Haleon. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.

About

Haleon is an Australian Private Company with ABN 68 603 310 292, registered in Victoria. The company adopted the trading name Haleon from 22 June 2022, having previously operated under the business name GlaxoSmithKline Consumer Healthcare. Haleon is currently active on the Australian Business Register.

Portfolio

Haleon maintains a portfolio of 23 brands on the ARTG, of which 5 are indexable brands that have cleared the SEO quality gate. Four brands have Product Information on file, one brand is PBS-listed, and one brand has PBAC outcome records. Notable brands in the portfolio include ADVIL, ADVILDUO, Aquaear, AURALGAN, Caltrate, Centrum, COMBIMOL, DE-GAS, DONNATAB, ENO, FLIXONASE, and HYDROZOLE.

Therapeutic focus

The portfolio is distributed across the following therapeutic areas: — Pain Management: 4 brands — Gastroenterology: 4 brands — Respiratory: 3 brands — Complementary Medicine: 3 brands — Pain & Anaesthesia: 3 brands — Infectious Disease: 3 brands — Musculoskeletal: 1 brand — Women's Health: 1 brand — Other: 1 brand

PBS footprint

One brand in the Haleon portfolio holds at least one PBS-listed item, with the portfolio most recently touching the PBS schedule on 1 May 2026.

Regulatory activity

The most recent PBAC outcome on record for Haleon is dated 1 March 2019, representing a single brand with PBAC outcome history.

ABR record